Labetuzumab govitecan Antibody-Drug Conjugate inhibitor | Read Reviews & Product Use Citations

Labetuzumab govitecan (IMMU-135) is a humanised anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody linked site-specifically to the active metabolite of irinotecan SN-38 via a proprietary linker. Labetuzumab govitecan can be used for research on colorectal cancer.

CAS No. 1469876-18-3

Click to purchase products related to Labetuzumab govitecan

Quality Control

Batch: D404801 Purity: 99% Protein concentration: 4.91 mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

99

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Labetuzumab govitecan (IMMU-135) is a humanised anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody linked site-specifically to the active metabolite of irinotecan SN-38 via a proprietary linker. Labetuzumab govitecan can be used for research on colorectal cancer.
References	[1] https://pubmed.ncbi.nlm.nih.gov/28817371/ [2] https://aacrjournals.org/cancerres/article/76/14_Supplement/CT065/613087/Abstract-CT065-Labetuzumab-govitecan-IMMU-130-an

Product Details

CAS No.	1469876-18-3
ADC antiody	Labetuzumab
ADC linker	Lysine; a maleimide-type cleavable linker
ADC cytotoxin	SN-38
Formulation	1xPBS
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.